Serum endocan and preoperative systemic inflammatory markers in patients with epilepsy

Özdemir, Ali; Kemerdere, Rahşan; Orhan, Bağnu; Emre, Hümeyra Öztürk; İnal, Berrin Berçik; Kayhan, Ahmet; Yenı, Seher Naz; Tanrıverdi, Taner

doi:10.1016/j.neuchi.2019.09.025

Cited by 10 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the previous studies, Ozdemir et al [ 26 ] prospectively studied a total of 21 epileptic patients who were going to have an epilepsy surgery and 21 healthy controls in 2019. They conducted this study to determine NLR values in patients undergoing surgery.…”

Section: Resultsmentioning

confidence: 99%

Neutrophil to Lymphocyte Ratio in Epilepsy: A Systematic Review

Hosseini

Mofrad

Mokarian

et al. 2022

Mediators of Inflammation

View full text Add to dashboard Cite

This study was conducted to summarize the results of studies investigating the role of neutrophil to lymphocyte ratio (NLR) in epilepsy. The search was conducted on PubMed, Scopus, and Web of Science up to December 25, 2021. Finally, a total of seven studies were included in the review. The NLR in patients who were in the acute phase was higher than that of healthy. NLR in the patients who were in either acute or subacute phase was higher than in healthy controls. A significant difference in NLR levels between the acute and subacute phases was also noted. Epilepsy is one of the most important neurological diseases in the world, and millions of people around the world suffer from it, and a cheap and fast biomarker is needed for it. The interesting thing is that inflammation plays a role in epilepsy, and elevated NLR value can be a good biomarker of inflammation and, as a result, for epilepsy.

show abstract

Section: Resultsmentioning

confidence: 99%

Neutrophil to Lymphocyte Ratio in Epilepsy: A Systematic Review

Hosseini

Mofrad

Mokarian

et al. 2022

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Serum levels of endocan, an inflammatory and angiogenesis-promoting molecule, and of preoperative inflammatory markers [neutrophil--lymphocyte ratio (NLR) and platelet--lymphocyte ratio (PLR)] were assessed in adult patients undergoing epilepsy surgery. Serum endocan levels correlated positively, but nonsignificantly, with the NLR and PLR in these patients [51].…”

Section: The Relation Between Novel Inflammatory Markers and Endocanmentioning

confidence: 68%

“…Angiogenesis and low-grade inflammation may play a role in the development and progression of epilepsy [51]. Serum levels of endocan, an inflammatory and angiogenesis-promoting molecule, and of preoperative inflammatory markers [neutrophil--lymphocyte ratio (NLR) and platelet--lymphocyte ratio (PLR)] were assessed in adult patients undergoing epilepsy surgery.…”

Section: The Relation Between Novel Inflammatory Markers and Endocanmentioning

confidence: 99%

Endocan: a new marker of endothelial function

Balta

Mikhailidis

2021

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of reviewTo consider the role of endocan as an inflammatory marker in cardiovascular diseases. Recent findingsEndocan, an endothelial inflammatory marker, is associated with cardiovascular disease. SummaryVascular endothelial inflammation plays a key role in the pathogenesis of inflammatory and cardiovascular diseases by influencing thrombogenesis, tumour invasion and secretion of bioactive mediators. We discuss the role of endocan mainly in the context of cardiology.

show abstract

“…Mertoglu et al ( 14 ) reported that increased endocan levels in fibromyalgia cases support the mechanisms of inflammation and endothelial dysfunction in the pathophysiology of fibromyalgia, and that endocan may even be an important marker in the diagnosis of fibromyalgia. Ozdemir et al ( 15 ) suggested that epileptogenic zone endocan levels increased in patients with epilepsy, and that endocan can, therefore, be employed as an inflammation index in these patients.…”

Section: Discussionmentioning

confidence: 99%

Endocan as a potential marker in diagnosis and predicting disease severity in COVID-19 patients: a promising biomarker for patients with false-negative RT-PCR

Laloğlu

Alay

2022

ujms

View full text Add to dashboard Cite

Background: Endothelial-specific molecule 1 (endocan) has emerged as an inflammatory biomarker in recent years. The purpose of this study was to investigate the diagnostic value of serum endocan levels in the prediction of COVID-19 disease among patients with a false-negative reverse transcription polymerase change reaction (RT-PCR) test, and also to determine its correlation with the clinical severity of the disease. Methods: Thirty patients with positive RT-PCR results and 30 with false-negative RT-PCR results, both with suspected COVID-19 in terms of clinical, radiological, and laboratory findings, were included in the study. Thirty healthy controls were also enrolled. Results: Serum endocan levels were estimated to be 821.8 ± 99.3 pg/mL in COVID-19 RT-PCR (+) patients, 803.9 ± 97.0 pg/mL in RT-PCR false (–) patients with suspected COVID-19, and 382.9 ± 37.5 pg/mL in the control group. No significant difference was observed between RT-PCR (+) and RT-PCR false (–) patients (P = 0.68). However, serum endocan levels differed significantly between patient groups and control group (P < 0.05). With a cut-off value of 444.2 pg/mL serum endocan levels differentiated COVID-19 cases from healthy individuals with 92% sensitivity and 80% specificity. Moreover, a significant positive correlation was observed between serum endocan levels and clinical severity (P < 0.01, r = 0.94). Conclusions: There is a need for different laboratory markers capable of assisting diagnosis and showing COVID-19 infection in suspected COVID-19 RT-PCR false-negative patients. Endocan levels can be used as an assistant blood test for identifying COVID-19 patients with false-negative RT-PCR tests and in determining the clinical severity of the disease.

show abstract

Serum endocan and preoperative systemic inflammatory markers in patients with epilepsy

Cited by 10 publications

References 36 publications

Neutrophil to Lymphocyte Ratio in Epilepsy: A Systematic Review

Neutrophil to Lymphocyte Ratio in Epilepsy: A Systematic Review

Endocan: a new marker of endothelial function

Endocan as a potential marker in diagnosis and predicting disease severity in COVID-19 patients: a promising biomarker for patients with false-negative RT-PCR

Contact Info

Product

Resources

About